Stereotactic Ultrahypofractionated MR-guided Radiotherapy for Localized Prostate Cancer - Acute Toxicity and Patient-reported Outcomes in the Prospective, Multicenter Phase II Trial

Overview

Journal Clin Transl Radiat Oncol

Specialty Oncology

Date 2024 Apr 8

PMID 38586081

Authors

C A Fink

J Ristau

C Buchele

S Kluter

J Liermann

P Hoegen-Sassmannshausen

E Sandrini

A Lentz-Hommertgen

L Baumann

N Andratschke

M Baumgartl

M Li

M Reiner

S Corradini

J Horner-Rieber

D Bonekamp

H-P Schlemmer

C Belka

M Guckenberger

J Debus

S A Koerber

Affiliations

Soon will be listed here.

Abstract

Background: Due to superior image quality and daily adaptive planning, MR-guided stereotactic body radiation therapy (MRgSBRT) has the potential to further widen the therapeutic window in radiotherapy of localized prostate cancer. This study reports on acute toxicity rates and patient-reported outcomes after MR-guided adaptive ultrahypofractionated radiotherapy for localized prostate cancer within the prospective, multicenter phase II trial.

Materials And Methods: A total of 69 patients with localized prostate cancer underwent MRgSBRT with daily online plan adaptation. Inclusion criteria comprised a tumor stage ≤ T3a, serum PSA value ≤ 20 ng/ml, ISUP Grade group ≤ 4. A dose of 37.5 Gy was prescribed to the PTV in five fractions on alternating days with an optional simultaneous boost of 40 Gy to the dominant intraprostatic lesion defined by multiparametric MRI. Acute genitourinary (GU-) and gastrointestinal (GI-) toxicity, as defined by CTCAE v. 5.0 and RTOG as well as patient-reported outcomes according to EORTC QLQ-C30 and -PR25 scores were analyzed at completion of radiotherapy, 6 and 12 weeks after radiotherapy and compared to baseline symptoms.

Results: There were no toxicity-related treatment discontinuations. At the 12-week follow-up visit, no grade 3 + toxicities were reported according to CTCAE. Up until the 12-week visit, in total 16 patients (23 %) experienced a grade 2 GU or GI toxicity. Toxicity rates peaked at the end of radiation therapy and subsided within the 12-week follow-up period. At the 12-week follow-up visit, no residual grade 2 GU toxicities were reported and 1 patient (1 %) had residual grade 2 enteritic symptoms. With exception to a significant improvement in the emotional functioning score following MRgSBRT, no clinically meaningful changes in the global health status nor in relevant subscores were reported.

Conclusion: Daily online-adaptive MRgSBRT for localized prostate cancer resulted in an excellent overall toxicity profile without any major negative impact on quality of life.

References

Salembier C, Villeirs G, De Bari B, Hoskin P, Pieters B, van Vulpen M . ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol. 2018; 127(1):49-61. DOI: 10.1016/j.radonc.2018.01.014. View

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196):385-395. DOI: 10.1016/S0140-6736(19)31131-6. View

Tree A, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D . Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022; 23(10):1308-1320. DOI: 10.1016/S1470-2045(22)00517-4. View

da Silva Mendes V, Nierer L, Li M, Corradini S, Reiner M, Kamp F . Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer. Radiat Oncol. 2021; 16(1):133. PMC: 8296626. DOI: 10.1186/s13014-021-01858-7. View

Brand D, Tree A, Ostler P, van der Voet H, Loblaw A, Chu W . Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019; 20(11):1531-1543. PMC: 6838670. DOI: 10.1016/S1470-2045(19)30569-8. View

Kishan A, Ma T, Lamb J, Casado M, Wilhalme H, Low D . Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol. 2023; 9(3):365-373. PMC: 9857817. DOI: 10.1001/jamaoncol.2022.6558. View

Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M . Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999; 44(4):921-9. DOI: 10.1016/s0360-3016(98)00502-1. View

Wahlstedt I, Andratschke N, Behrens C, Ehrbar S, Gabrys H, Garcia Schuler H . Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer. Radiother Oncol. 2022; 170:205-212. DOI: 10.1016/j.radonc.2022.03.013. View

Ristau J, Horner-Rieber J, Buchele C, Kluter S, Jakel C, Baumann L . Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial. Radiat Oncol. 2022; 17(1):75. PMC: 9011377. DOI: 10.1186/s13014-022-02047-w. View

10.

Dassen M, Janssen T, Kusters M, Pos F, Kerkmeijer L, van der Heide U . Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: Implications for treatment margins. Radiother Oncol. 2023; 186:109761. DOI: 10.1016/j.radonc.2023.109761. View

11.

Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

12.

De Cock L, Draulans C, Pos F, Isebaert S, De Roover R, van der Heide U . From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol. 2023; 185:109713. DOI: 10.1016/j.radonc.2023.109713. View

13.

DAmico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick G . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11):969-74. DOI: 10.1001/jama.280.11.969. View

14.

Christiansen R, Dysager L, Hansen C, Jensen H, Schytte T, Nyborg C . Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment. Radiother Oncol. 2021; 167:165-171. DOI: 10.1016/j.radonc.2021.12.013. View

15.

Le Guevelou J, Bosetti D, Castronovo F, Angrisani A, de Crevoisier R, Zilli T . State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature. World J Urol. 2023; 41(11):3287-3299. PMC: 10632210. DOI: 10.1007/s00345-023-04579-6. View

16.

Teunissen F, Willigenburg T, Tree A, Hall W, Choi S, Choudhury A . Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. Pract Radiat Oncol. 2022; 13(3):e261-e269. DOI: 10.1016/j.prro.2022.09.007. View

17.

Bruynzeel A, Tetar S, Oei S, Senan S, Haasbeek C, Spoelstra F . A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Int J Radiat Oncol Biol Phys. 2019; 105(5):1086-1094. DOI: 10.1016/j.ijrobp.2019.08.007. View

18.

Kerkmeijer L, Groen V, Pos F, Haustermans K, Monninkhof E, Smeenk R . Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol. 2021; 39(7):787-796. DOI: 10.1200/JCO.20.02873. View

19.

Kluter S . Technical design and concept of a 0.35 T MR-Linac. Clin Transl Radiat Oncol. 2019; 18:98-101. PMC: 6630153. DOI: 10.1016/j.ctro.2019.04.007. View

20.

Arrayeh E, Westphalen A, Kurhanewicz J, Roach 3rd M, Jung A, Carroll P . Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012; 82(5):e787-93. PMC: 3285390. DOI: 10.1016/j.ijrobp.2011.11.030. View